Clinical trial
Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
NCT00377962 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00377962 |
|---|---|
| Title | Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation |
| Official title | Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation: Results at 24 Months |
| Acronym | NOCTET |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Disorder Related to Cardiac Transplantation |
| Intervention type | Drug |
| Interventions | Everolimus, Mycophenolic acid (MPA)/azathioprine (AZA), Calcineurin inhibitors (CNI), Steroids |
| Enrollment | 282 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Sep 19, 2006 |
| Last update posted | Jul 30, 2020 |
| Countries | Denmark, Norway, Sweden |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: